Molnupiravir and Nirmatrelvir/Ritonavir: Tolerability, Safety, and Adherence in a Retrospective Cohort Study

Background. Molnupiravir (MOL) and nirmatrelvir/ritonavir (NIR) were recently approved for the early treatment of COVID-19, but real-life data on tolerability, safety, and adverse events (AEs) are still scarce. Methods. We conducted a retrospective cohort study including all patients who were prescr...

詳細記述

書誌詳細

主要な著者:	Maria Mazzitelli, Daniele Mengato, Lolita Sasset, Anna Ferrari, Samuele Gardin, Vincenzo Scaglione, Nicola Bonadiman, Lucrezia Calandrino, Silvia Cavinato, Sabrina Trivellato, Francesca Venturini, Anna Maria Cattelan
フォーマット:	Artigo
言語:	Inglês
出版事項:	MDPI AG 2023-01-01
シリーズ:	Viruses
主題:	molnupiravir nirmatrelvir/ritonavir tolerability adverse drug reaction adherence COVID-19
オンライン･アクセス:	https://www.mdpi.com/1999-4915/15/2/384
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!